OCH, a molecule designed to have beneficial effects on immune regulation in multiple sclerosis (MS), led to increases in regulatory immune cell subsets and immunomodulatory gene activity in healthy volunteers and MS patients.
That’s according to data from a first-in-human study of the compound, which also found the immune regulation treatment to be generally safe.
An ongoing Phase 2 trial (NCT04211740) is now assessing OCH’s safety and efficacy in 30 MS patients at a single center in Japan. That trial is expected to finish later this year.
